嘉戎技術(301148.SZ):擬以3000萬元向優尼索增資 用於DTRO膜組件產能擴充及特種分離膜組件產業化項目
格隆匯5月17日丨嘉戎技術(301148.SZ)公佈,公司於2022年5月17日召開了第三屆董事會第五次會議和第三屆監事會第五次會議,審議通過了《關於使用募集資金對子公司增資以實施募投項目的議案》,同意公司使用募集資金3000萬元向全資子公司優尼索膜技術(廈門)有限公司(“優尼索”)進行增資,用於實施“DTRO膜組件產能擴充及特種分離膜組件產業化項目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.